<DOC>
	<DOCNO>NCT00625729</DOCNO>
	<brief_summary>RATIONALE : Aldesleukin may stimulate natural killer cell kill cancer cell . Treating natural killer cell aldesleukin laboratory may help natural killer cell kill cancer cell put back body . Giving monoclonal antibody , rituximab , chemotherapy drug , fludarabine cyclophosphamide , donor natural killer cell infusion help stop growth cancer cell . It also help stop patient 's immune system reject donor 's stem cell . PURPOSE : This phase I/II trial study well give rituximab chemotherapy follow donor natural killer cell infusion treat laboratory aldesleukin follow aldesleukin work treat patient non-Hodgkin lymphoma chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Donor Natural Killer Cell Infusion , Rituximab , Aldesleukin , Chemotherapy Treating Patients With Relapsed Non-Hodgkin Lymphoma Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine allogeneic natural killer ( NK ) cell infuse follow chemoimmunotherapy safely expand vivo aldesleukin . Secondary - To determine interleukin-15 production day 0 correlate NK cell expansion . - To determine overall response rate 3 month . - To determine time progression overall survival . - To characterize quantitative qualitative toxicity treatment plan . - To determine incidence donor product meet release criterion NK cell number infuse . - To correlate clinical response donor/recipient KIR ligand match status , FcG receptor 3A genotype , NK cell phenotype function - To determine pharmacodynamic pharmacogenomic marker correlate NK cell expansion disease response . OUTLINE : - Conditioning regimen : Patients receive rituximab intravenously ( IV ) 6-8 hour day -8 , -1 , 6 , 13 ; fludarabine IV day -6 -2 ; cyclophosphamide IV day -5 . - Allogeneic natural killer ( NK ) cell administration : Patients receive aldesleukin-activated haploidentical NK cell IV le 1 hour day 0 . Within 4 hour allogeneic NK cell infusion , patient receive aldesleukin subcutaneously ( SC ) 3 time week 6 dos . Patients also receive filgrastim ( G-CSF ) SC begin day 14 continue absolute neutrophil count ( ANC ) &gt; 2,500/mm³ 2 consecutive day . Patients achieve complete partial response 28 day eligible allogeneic stem cell transplantation . Patients achieve initial response 3 month , clinically benefit treatment , subsequently relapse eligible retreatment provide eligibility criterion meet . Blood sample collect periodically correlative laboratory study . Patients chronic lymphocytic leukemia ( CLL ) also undergo bone marrow aspiration periodically correlative laboratory study . After completion study treatment , patient follow periodically 1 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Patient 18 year old diagnosis nonHodgkin Lymphoma chronic lymphocytic leukemia ( NHL CLL ) one following : Progression NHL follow least 2 prior chemotherapy regimen , ( must contain rituximab NHL fludarabine follicular NHL ) define : failure achieve partial remission ( PR ) last chemotherapy disease progression within 6 month follow last chemotherapy Progression CLL/SLL ( small lymphocytic lymphoma ) follow least 2 prior chemotherapy regimen ( contain purine analog ) stage Rai III IV symptomatic disease . Relapsed NHL CLL follow stem cell transplantation option donor lymphocyte infusion available clinically indicate ( e.g . recipient autologous umbilical cord blood [ UCB ] transplant ) . Available related HLAhaploidentical ( human leukocyte antigen ) natural killer ( NK ) cell adult donor least Class I serologic type Karnofsky performance status &gt; 60 % Measurable disease base modify Response Evaluation Criteria In Solid Tumors ( RECIST ) Have acceptable organ function define within 28 day enrollment : Hematologic : platelet ≥ 80,000 x 10^9/L ; hemoglobin ≥ 9g/dL , unsupported transfusion ; absolute neutrophil count ( ANC ) ≥ 1000 x 10^9/L , unsupported granulocytecolony stimulate factor granulocytemacrophage colonystimulating factor ( GCSF GMCS ) F 10 day Neulasta 21 day hematologic requirement waive patient inadequate count due know bone marrow involvement lymphoma otherwise eligible Renal : glomerular filtration rate ( GFR ) &gt; 50 ml/min Hepatic : alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) &lt; 3 x upper limit normal total bilirubin &lt; 3 mg/dl Pulmonary function : &gt; 50 % correct carbon monoxide diffuse capacity ( DLCO ) Forced Expiratory Volume first second ( FEV1 ) Cardiac : symptom uncontrolled cardiac disease , leave ventricular ejection fraction &gt; 40 % Off prednisone immunosuppressive medication least 3 day prior Day 0 Women childbearing potential must agree use adequate contraception ( diaphragm , birth control pill , injection , intrauterine device [ IUD ] , surgical sterilization , subcutaneous implant , abstinence , etc . ) duration treatment . Voluntary write informed consent performance studyrelated procedure part normal medical care . Pregnant lactating . The agent use study may teratogenic fetus information excretion agent breast milk . All female childbearing potential must blood test urine study within 2 week prior registration rule pregnancy . Women childbearing age must use appropriate contraceptive method . Active central nervous system ( CNS ) lymphoma/leukemia Active serious infection ( pulmonary infiltrates lesion allow appropriate diagnostic test negative infection appropriate therapy initiate probable infection ) Pleural effusion large enough detectable chest xray Allergy rituximab IL2 Human immunodeficiency virus ( HIV ) associate nonHodgkins lymphoma ( NHL ) Active concurrent malignancy ( except skin cancer ) require systemic therapy past 2 year EpsteinBarr virus ( EBV ) posttransplant lymphoproliferative disorder Positive hepatitis B surface antigen ( HBsAg ) . If Hepatitis B core antibody ( HBcAb ) positive , Hepatitis B deoxyribonucleic acid ( DNA ) polymerase chain reaction ( PCR ) evaluate . Positive anti HBcAb undetectable viral load exclude patient . Any experimental therapy past 30 day Donor Selection : Related donor ( sibling , parent , offspring , parent offspring HLA identical sibling ) ≥ age 18 year Able willing undergo lymphapheresis HLAhaploidentical donor/recipient match . If time permit multiple donor available , preference give Killercell Immunoglobulinlike Receptors ( KIR ) ligand mismatch donor ( predict HLA type ) . HIV1 , HIV2 negative , Human Tlymphotropic virus Type I ( HTLV1 ) , HTLV2 negative , West Nile virus ( WNV ) negative , Hepatitis B C negative Adequate organ function define : Hematologic : CBC/diff/platelet count near normal limit , Hepatic : ALT &lt; 2 x upper limit normal , Not pregnant lactating In general good health determine study physician Able give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
</DOC>